|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||174.04 - 174.85|
|52 Week Range||148.31 - 181.92|
|PE Ratio (TTM)||72.09|
|Beta (3Y Monthly)||0.98|
|Expense Ratio (net)||0.10%|
Is Johnson & Johnson an Attractive Buy after Q4 Results?Stock price movementsOn January 28, Johnson & Johnson (JNJ) closed at $128.99, which is 0.63% higher than its previous closing price. The company closed at a premium of 8.74% as
With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs.
Johnson & Johnson expects its sales growth to slow down this year due to pricing pressures and generic-drug competition for its pharmaceutical division. This has put healthcare ETFs in focus.
Shares of Abbott Laboratories fell 2.7% in premarket trade Wednesday after the company reported fourth-quarter results that met earnings expectations but fell short on revenue. Profit for the latest quarter rose to $654 million, or 37 cents a share, after a loss of $828 million, or a loss of 48 cents a share in the year-earlier quarter. Adjusted EPS was 81 cents a share, matching the FactSet consensus. Revenue was $7.765 billion, falling short of the FactSet consensus of $7.815 billion, but up from $7.589 one year ago. Revenue from Abbott's nutrition segment fell 0.4% to $1.777 billion, while revenue from its diagnostics segment rose 2.9% to $1.961 billion. Its established pharmaceuticals segment brought in $1.09 billion, down 4.8% from the year earlier, and revenue for Abbott's medical devices segment rose 6.7% to $2.92 billion. The company expects EPS of 25 cents to 27 cents for the first quarter of 2019, and full-year adjusted EPS of $3.15 to $3.25. The company also announced an 14% increase in quarterly dividend to 32 cents per share from 28 cents per share. Shares of Abbott have fallen 1.2% in the year to date through Tuesday, while the S&P 500 has gained 5%. The Vanguard Health Care ETF has gained 4.3%.
How to Invest Like Jeff Bezos: The Top Three Sectors to WatchJeff Bezos’s investmentsJeff Bezos, Amazon’s (AMZN) founder and CEO, topped Forbes’s list of the world’s billionaires in 2018. According to the list, he had $112 billion in
Teva or Mylan: Which Is the Better Generic Play in January? (Continued from Prior Part) ## MYL’s price movements On January 8, Mylan (MYL) closed at $29.87, up 0.40% from its previous closing price. The company closed at a premium of 14.73% to its 52-week low price of $26.03 and at a discount of 37.54% to its 52-week high price of $47.82. As of January 8, Mylan’s market cap is $15.37 billion. The company is trading at a trailing PE ratio of 24.13x and a forward PE ratio of 5.85x. Based on its closing price on January 8, the company had reported returns of 9.01% in the last week, -6.19% in the last month, and -15.36% in the last quarter. It had also reported returns of -19.51% in the last half year, -32.94% in the last year, and 9.01% YTD (year-to-date). Based on its closing price on January 7, the US healthcare sector represented by the Vanguard Health Care ETF (VHT) had reported returns of 1.47% in the last week, -6.03% in the last month, and -8.31% in the last quarter. VHT had also reported returns of -1.45% in the last half year, 2.56% in the last year, and 1.47% YTD. ## Analysts’ recommendations and target prices for Mylan The 12-month consensus analyst recommendation for Mylan as of January 9 is a “buy.” The 12-month consensus target price for the company is $42.63, 42.72% higher than its closing price on January 8. The highest target price estimate for the company is $55, and the lowest target price estimate is $28. Of the 17 analysts covering Mylan on January 9, seven analysts have rated the company as a “strong buy,” six have rated it as a “buy,” and four have rated it as a “hold.” In the next article, we’ll compare the revenue growth prospects of Teva Pharmaceutical and Mylan in greater detail. Continue to Next Part Browse this series on Market Realist: * Part 1 - What Analysts Are Recommending for Teva Pharmaceutical in January * Part 3 - Teva or Mylan: Who Has the More Promising Revenue Trajectory? * Part 4 - Teva or Mylan: Whose Earnings Are Growing Faster?
Three Healthcare Stocks Rallying Over 10% Today ## Three healthcare stocks The broader market is trading in the green territory today but largely on a mixed note compared to the volatility in the previous couple of sessions. At 11:40 AM ET, the S&P 500 Index (SPY), NASDAQ Composite Index (QQQ), and Dow Jones Industrial Average were trading with 0.8%, 1.1%, and 0.6% gains. However, some healthcare stocks (XLV)(VHT)(IBB) were making huge moves today. Let’s take a look. ## Loxo Oncology Today before the market opened, the American pharmaceutical giant Eli Lilly and Company (LLY) announced the acquisition of Loxo Oncology (LOXO). According to the agreement between the two companies, Eli Lilly will acquire Loxo for $235.00 per share in cash, which translates into approximately $8.0 billion. After the news came out, Loxo stock surged nearly 66.0% to $232.12. ## Sage Therapeutics The biopharmaceutical firm Sage Therapeutics (SAGE) revealed positive results of the Phase 3 ROBIN Study today. The outcome of the study suggested a “significant improvement” in women with postpartum depression (or PPD) who were treated with its SAGE-217 drug for two weeks. This news boosted investors’ confidence, and SAGE stock surged 62.1% to a day high of $158.09. ## Exact Sciences The molecular diagnostics firm Exact Sciences (EXAS) said today that it expects its fourth quarter of 2018 revenue between $142.5 million and $143.5 million, which reflected about a 64% rise in its revenue from the fourth quarter of the previous year. In a press release, the company said that it “completed approximately 292,000 Cologuard tests during the fourth quarter of 2018,” up about 66% year-over-year. Plus, Exact Sciences noted, “Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018.” These positive developments drove EXAS stock to rally today to post a day high of $72.78, up 11.0% from its previous session’s closing price. Note that in 2018, LOXO, LLY, and EXAS rose 66.4%, 37.0%, and 20.1%, respectively, while SAGE fell 41.8%.
Compared to other sectors, healthcare was sturdy in 2018 and while the sector looks close to being fairly valued, the group could offer more upside this year. The Health Care Select Sector SPDR ETF (XLV) , the largest healthcare ETF by assets, gained 6.30% last year. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.
While millennials are doing a good job of saving in traditional ways, not parking their money in high-return investment options could be a potential mistake.
The U.S. equity rally is beginning to lose steam and investors should not expect markets to maintain their breakneck spurt of yesteryear. Nevertheless, traders may still find value in some battered sectors ...
As U.S. markets continue to wobble, investors who want to stay in the game can look to defensive sector-related ETFs for a more steady approach. “If the sell-off continues and it deepens, it’s going to ...
Even as the Democrats retook control of the House of Representatives and the Republicans maintained majority in the Senate, healthcare ETFs were also big winners following the 2018 Midterm Election results. ...
The Department of Justice issued a preliminary approval for CVS Pharmacy to acquire health care insurance company Aetna, possibly paving the way for transformative changes in the industry as cries for more affordable care emanating from consumers and regulators get louder. The Health Care Select Sector SPDR ETF (XLV) slid 0.42% as of 11:45 a.m. ET, Vanguard Health Care ETF (VHT) fell 0.54%, iShares US Medical Devices ETF (IHI) was down 1.21%, and iShares US Healthcare ETF (IYH) slid 0.55%. As part of the approval process, the DOJ set forth the condition that Aetna had to divest itself from its Medicare Part D drug plan, which it eventually sold to WellCare Health Plans for an undisclosed amount late last month.